Synedgen Selected as Showcase Company to Present at SoCalBio Conference
Conference highlights the strength and future of the Los Angeles area bioscience industry
October 30, 2012–Claremont CA—Synedgen will be highlighted at the 14th annual SoCalBio Investor Conference next week in Los Angeles following a competitive selection to showcase promising companies identified by the the Southern California Biomedical Council.
Synedgen President and COO, Shenda Baker, PhD will discuss the partnering opportunities for three products that are moving quickly into human clinical trials. These products represent targets for strategic partnering at an early stage in development, where the potential for early translation to the market place is enhanced by potential orphan status for two of the products and coupled with strong pre-clinical efficacy data, a high safety profile, and extensive government funding support. Dr. Baker will highlight Synazalt™, a mucolytic for clearing the sinuses of patients with Cystic Fibrosis; Catasyn™, a wound rinse that removes biofilms, prevents infection and stimulates healing; and Regenasyn™, an oral, topical treatment to reduce the oral lesions associated with radiation therapies for head and neck cancer.
“Synedgen is honored to be selected as a presenter for this year’s conference,” said Baker. “We look forward to discussing our product development successes and networking with area bioscience industry stakeholders.”
The Southern California Biomedical Council (SoCalBio) is the trade association of the life-science industry in the Greater Los Angeles region, representing and promoting the medical device and biotechnology industries for job creation and economic development.
The event will be held at the Omni Hotel in downtown Los Angeles.